Dysregulated signaling pathways in the development of CNTRL-FGFR1–induced myeloid and lymphoid malignancies associated with FGFR1 in human and mouse models

Blood

Volumn 122, Issue 6, 2013, Pages 1007-1016

  Ren, Mingqiang ^a   Qin, Haiyan ^a   Kitamura, Eiko ^a   Cowell, John K ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; CD34 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CNTRL PROTEIN; CSF1R PROTEIN; EBF1 PROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FLT3 LIGAND; GFI1 PROTEIN; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 3; KIT PROTEIN; KRUPPEL LIKE FACTOR 4; MYC PROTEIN; NOTCH1 RECEPTOR; PONATINIB; PROTEIN; SPI1 PROTEIN; TCRA PROTEIN; TRANSCRIPTION FACTOR PAX5; UNCLASSIFIED DRUG; VPREB1 PROTEIN; CELL CYCLE PROTEIN; CNTRL PROTEIN, HUMAN; FGFR1 PROTEIN, HUMAN; FLT3 LIGAND PROTEIN; IMMUNOGLOBULIN; MEMBRANE PROTEIN; STEM CELL FACTOR RECEPTOR;

ACUTE MYELOID LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CANCER GROWTH; CELL DIFFERENTIATION; CLONAL EVOLUTION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME ACTIVATION; FEMALE; GENETIC ANALYSIS; HEMATOPOIETIC STEM CELL; HEPATOSPLENOMEGALY; HUMAN; HUMAN CELL; LATENT PERIOD; LEUKEMOGENESIS; MALE; MOLECULAR PATHOLOGY; MOUSE; MYELOID PROGENITOR CELL; MYELOPROLIFERATIVE NEOPLASM; NOD SCID MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T CELL LEUKEMIA; T LYMPHOCYTE; ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL; CELL CULTURE; CYTOLOGY; DISEASE MODEL; GENE LIBRARY; GENETICS; METABOLISM; MYELOPROLIFERATIVE DISORDER; NUCLEOTIDE SEQUENCE; PHENOTYPE; STEM CELL; T CELL LYMPHOMA;

ANIMALS; ANTIGENS, CD34; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DNA MUTATIONAL ANALYSIS; GENE LIBRARY; HUMANS; IMMUNOGLOBULINS; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, T-CELL; MEMBRANE PROTEINS; MICE; MYELOPROLIFERATIVE DISORDERS; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-KIT; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; SIGNAL TRANSDUCTION; STEM CELLS;

EID: 84886895019     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-03-489823     Document Type: Article

References (42)

1. Jackson CC, Medeiros LJ, Miranda RN. 8p11 myeloproliferative syndrome: a review. Hum Pathol. 2010;41(4):461-476.
2. Chen J, Deangelo DJ, Kutok JL, et al. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci USA. 2004;101(40): 14479-14484.
3. Ren M, Li X, Cowell JK. Genetic fingerprinting of the development and progression of T-cell lymphoma in a murine model of atypical myeloproliferative disorder initiated by the ZNF198-fibroblast growth factor receptor-1 chimeric tyrosine kinase. Blood. 2009;114(8): 1576-1584.
4. Ren M, Tidwell JA, Sharma S, Cowell JK. Acute progression of BCR-FGFR1 induced murine B-lympho/myeloproliferative disorder suggests involvement of lineages at the pro-B cell stage. PLoS ONE. 2012;7(6):e38265.
5. Roumiantsev S, Krause DS, Neumann CA, et al. Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. Cancer Cell. 2004;5(3):287-298.
6. Hu S, He Y, Zhu X, Li J, He H. Myeloproliferative disorders with t(8;9)(p12;q33): a case report and review of the literature. Pediatr Hematol Oncol. 2011;28(2):140-146.
7. Park TS, Song J, Kim JS, et al. 8p11 myeloproliferative syndrome preceded by t(8;9) (p11;q33), CEP110/FGFR1 fusion transcript: morphologic, molecular, and cytogenetic characterization of myeloid neoplasms associated with eosinophilia and FGFR1 abnormality. Cancer Genet Cytogenet. 2008;181(2):93-99.
8. Post GR, Holloman D, Christiansen L, Smith J, Stuart R, Lazarchick J. Translocation t(3;8;9) (p25;p21;q34) in a patient with features of 8p11 myeloproliferative syndrome: a unique case and review of the literature. Leuk Res. 2010;34(11): 1543-1544.
9. Yamamoto K, Kawano H, Nishikawa S, Yakushijin K, Okamura A, Matsui T. A biphenotypic transformation of 8p11 myeloproliferative syndrome with CEP1/FGFR1 fusion gene. Eur J Haematol. 2006;77(4): 349-354.
10. Williams DA, Tao W, Yang F, et al. Dominant negative mutation of the hematopoietic-specific Rho GTPase, Rac2, is associated with a human phagocyte immunodeficiency. Blood. 2000;96(5): 1646-1654.
11. Ren M, Qin H, Ren R, Cowell JK. Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities. Leukemia. 2013;27(1):32-40.
12. Ren M, Cowell JK. Constitutive Notch pathway activation in murine ZMYM2-FGFR1-induced T-cell lymphomas associated with atypical myeloproliferative disease. Blood. 2011;117(25): 6837-6847.
13. Deshpande AJ, Cusan M, Rawat VP, et al. Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia. Cancer Cell. 2006;10(5):363-374.
14. Yamamoto S, Ebihara Y, Mochizuki S, et al. Letter to the Editor: quantitative PCR detection of CEP110-FGFR1 fusion gene in a patient with 8p11 syndrome. Leuk Lymphoma. 2013;Feb. 16.
15. Mandel EM, Grosschedl R. Transcription control of early B cell differentiation. Curr Opin Immunol. 2010;22(2):161-167.
16. Santos PM, Borghesi L. Molecular resolution of the B cell landscape. Curr Opin Immunol. 2011; 23(2):163-170.
17. Mombaerts P, Mizoguchi E, Grusby MJ, Glimcher LH, Bhan AK, Tonegawa S. Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell. 1993;75(2): 274-282.
18. Philpott KL, Viney JL, Kay G, et al. Lymphoid development in mice congenitally lacking T cell receptor alpha beta-expressing cells. Science. 1992;256(5062):1448-1452.
19. Palomero T, Sulis ML, Cortina M, et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med. 2007; 13(10):1203-1210.
20. Doulatov S, Notta F, Laurenti E, Dick JE. Hematopoiesis: a human perspective. Cell Stem Cell. 2012;10(2):120-136.
21. Feinberg MW, Wara AK, Cao Z, et al. The Kruppel-like factor KLF4 is a critical regulator of monocyte differentiation. EMBO J. 2007;26(18): 4138-4148.
22. Laiosa CV, Stadtfeld M, Graf T. Determinants of lymphoid-myeloid lineage diversification. Annu Rev Immunol. 2006;24:705-738.
23. Rosenbauer F, Tenen DG. Transcription factors in myeloid development: balancing differentiation with transformation. Nat Rev Immunol. 2007;7(2): 105-117.
24. Luo H, Li Q, O’Neal J, Kreisel F, Le Beau MM, Tomasson MH. c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations. Blood. 2005;106(7):2452-2461.
25. Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003;3(9):650-665.
26. van der Meer LT, Jansen JH, van der Reijden BA. Gfi1 and Gfi1b: key regulators of hematopoiesis. Leukemia. 2010;24(11):1834-1843.
27. O’Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16(5):401-412.
28. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146(6):904-917.
29. Zhou L, Fu W, Yuan Z, Hou J. Complete molecular remission after interferon alpha treatment in a case of 8p11 myeloproliferative syndrome. Leuk Res. 2010;34(11):e306-e307.
30. Hoffman B, Amanullah A, Shafarenko M, Liebermann DA. The proto-oncogene c-myc in hematopoietic development and leukemogenesis. Oncogene. 2002;21(21):3414-3421.
31. Inhorn RC, Aster JC, Roach SA, et al. A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity. Blood. 1995; 85(7):1881-1887.
32. Macdonald D, Aguiar RC, Mason PJ, Goldman JM, Cross NC. A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review. Leukemia. 1995;9(10): 1628-1630.
33. Vega F, Medeiros LJ, Davuluri R, Cromwell CC, Alkan S, Abruzzo LV. t(8;13)-positive bilineal lymphomas: report of 6 cases. Am J Surg Pathol. 2008;32(1):14-20.
34. Wei J, Wunderlich M, Fox C, et al. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. Cancer Cell. 2008;13(6):483-495.
35. Krawczuk-Rybak M, Zak J, Jaworowska B. A lineage switch from AML to ALL with persistent translocation t(4;11) in congenital leukemia. Med Pediatr Oncol. 2003;41(1):95-96.
36. Lounici A, Cony-Makhoul P, Dubus P, Lacombe F, Merlio JP, Reiffers J. Lineage switch from acute myeloid leukemia to acute lymphoblastic leukemia: report of an adult case and review of the literature. Am J Hematol. 2000;65(4):319-321.
37. Lu M, Kawamoto H, Katsube Y, Ikawa T, Katsura Y. The common myelolymphoid progenitor: a key intermediate stage in hemopoiesis generating T and B cells. J Immunol. 2002;169(7):3519-3525.
38. Katsura Y. Redefinition of lymphoid progenitors. Nat Rev Immunol. 2002;2(2):127-132.
39. Kawamoto H. A close developmental relationship between the lymphoid and myeloid lineages. Trends Immunol. 2006;27(4):169-175.
40. Shultz LD, Lyons BL, Burzenski LM, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol. 2005;174(10):6477-6489.
41. Agerstam H, Järås M, Andersson A, et al. Modeling the human 8p11-myeloproliferative syndrome in immunodeficient mice. Blood. 2010; 116(12):2103-2111.
42. Risueño RM, Campbell CJ, Dingwall S, et al. Identification of T-lymphocytic leukemia-initiating stem cells residing in a small subset of patients with acute myeloid leukemic disease. Blood. 2011;117(26):7112-7120.